Skip to content

Preventing miscarriage through platform testing of multiple novel interventions

PREMIS: Preventing miscarriage through platform testing of multiple (novel) interventions. Intervention 1: DHA trial: Docosahexaenoic acid (DHA) (omega-3) to improve live birth rate in women with previous miscarriage

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN78792722
Enrollment
1943
Registered
2026-02-24
Start date
2026-10-01
Completion date
Unknown
Last updated
2026-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Medical condition: Miscarriage Medical condition in lay language: Miscarriage Therapeutic areas: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] Pregnancy and Childbirth

Interventions

Randomisation will be conducted by a computer algorithm in a 1:1:1 (control:intervention:intervention) ratio to either the control arm, omega-3 intervention low-dose arm (750mg) or the high-dose arm (

Sponsors

University of Birmingham
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
16 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Written informed consent to receive DHA (omega-3) supplements 2. Patient confirmation of positive pregnancy test 3. Fish consumption - 0, 1 or 2 portions per week (1 portion defined as 140g or 4.9oz when cooked)

Exclusion criteria

Exclusion criteria: 1. Currently taking omega-3 supplementation with DHA concentration >300mg and unwilling to stop 2. Sensitive or allergic to fish or seafood

Design outcomes

Primary

MeasureTime frame
Definitive (D) primary outcome: Live births = 34 weeks of gestation as a proportion of all women randomised measured using data collected from medical records at one timepoint at the pregnancy end;Intermediate (I) primary outcome: Ongoing pregnancies at 11 – 14 weeks of gestation as a proportion of all women randomised measured using data collected from medical records at one timepoint at the end of the study

Secondary

MeasureTime frame
The following secondary outcome measures will be collected using a questionnaire at one timepoint: 1. Miscarriage rate (defined as delivery before 24 weeks of gestation) 2. Live birth <34 weeks 3. Ectopic pregnancy 4. Termination 5. Stillbirth 6. Molar pregnancy 7. Multiple pregnancy 8. Gestational age at miscarriage 9. Gestational age at live birth 10. First-trimester miscarriage, defined as loss of pregnancy up to 13 weeks and 6 days 11. Early first-trimester miscarriage, defined as loss of pregnancy up to 7 weeks and 6 days 12. Late first-trimester miscarriage, defined as loss of pregnancy between 8 weeks and 0 days and up to 13 weeks and 6 days 13. Second-trimester miscarriage, defined as loss of pregnancy between 14 weeks and 0 days and up to 23 weeks and 6 days 14. Where live birth =24 weeks: gestational age <28/<32/<37 weeks 15. Mode of delivery (unassisted vaginal, instrumental vaginal, elective caesarean section, emergency caesarean section, vaginal breech delivery, other) 16. Birth weight 17. Antenatal complications: antepartum haemorrhage, pregnancy-induced hypertension, pre-eclampsia, obstetric cholestasis, cervical cerclage, preterm (<37 weeks) pre-labour rupture of membranes, gestational diabetes, fetal growth restriction, small for gestational age, macrosomia. Other complications will be tabulated but not formally analysed. 18. Post-partum complications: haemorrhage (other complications will be tabulated but not formally analysed) 19. Maternal complications: admission to high dependency unit (HDU) or intensive therapy unit (ITU) (other complications will be tabulated but not formally analysed) 20. Maternal mental health: confirmed diagnosis or sought medical support for a psychological disorder related to miscarriage 21. Neonatal complications: admission to neonatal care unit (neonatal intensive care unit [NICU] or Special Care Baby Unit [SCBU]) (other complications will be tabulated but not formally analysed); congenital and chromosomal abnormalities

Countries

England, Northern Ireland, Scotland, United Kingdom, Wales

Contacts

Public ContactLee Priest
l.priest.1@bham.ac.uk-

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Sep 19, 2026